India Advances Oral Nanodrug Development to Combat Newborn Jaundice

India is accelerating the development and commercial manufacturing of an oral nanodrug designed to treat neonatal hyperbilirubinemia, a severe form of jaundice affecting infants. According to government documents reviewed by media, the Indian Council of Medical Research (ICMR) is inviting pharmaceutical manufacturers to produce clinical trial batches of the formulation to provide an accessible alternative to hospital-based phototherapy and blood transfusions.

Citrate-functionalized manganese oxide nanoparticles represent the only drug since tin-mesoporphyrin to demonstrate clinical efficacy to reverse hyperbilirubinemia in human neonates.

The Indian Council of Medical Research set a submission deadline of October 21, 2026 for manufacturers to submit Expressions of Interest for developing C-Mn3O4 NP nanodrug clinical trial formulations.

Projected commercial manufacturing costs per dose for the oral C-Mn3O4 nanodrug have not been officially disclosed in ICMR's Expression of Interest or trial documents.

Neonatal jaundice is caused by the accumulation of bilirubin in the blood. While mild cases resolve spontaneously, acute instances allow the pigment to cross into the infant brain, risking neurological damage, hearing loss, or mortality. Severe jaundice accounts for 15% to 25% of neonatal hospital admissions in India and carries a 5% to 10% case fatality rate. Traditional treatments rely on specialized phototherapy units or exchange transfusions, which demand costly hospital infrastructure and reliable electricity.

Nanodrug Mechanism and Preclinical Results

The oral medicine uses targeted nanoparticles designed to bind with bilirubin, converting the pigment into a harmless compound excreted naturally through urine and stool. Preclinical animal studies and early trials demonstrated that the single-dose formulation reduced brain toxin levels by nearly 85% within hours. Trials also indicated a 94% reduction in neonatal mortality and a 92% decrease in exchange transfusion requirements while shortening the duration infants needed under phototherapy lights.

Dr. Sameer Punia, a pediatric intensivist at Aakash Healthcare Superspeciality Hospital, noted that an indigenous, affordable oral nanodrug administered at the point of care could significantly improve access in resource-limited settings.

Manufacturing Partnerships and Next Steps

Under the proposed ICMR framework, selected pharmaceutical partners will secure commercialization and manufacturing rights across various dosage strengths. Partner companies will take the formulation through safety evaluations toward commercial approval while producing standardized trial batches. Queries sent to the Ministry of Health and Family Welfare and the ICMR regarding the timeline remained unanswered.

Specific clinical trial completion and CDSCO filing deadlines remain undecided, as ICMR's official invitation specifies that study timelines will be determined later under the collaborative agreement.

Why a laboratory nanodrug is not yet a newborn treatment

Neonatal jaundice is common, but its management depends on the infant's bilirubin level, age in hours and clinical risk factors. Research into an oral delivery method is scientifically interesting only if it ultimately demonstrates a clear safety and treatment benefit in appropriate human studies. Laboratory or animal results cannot establish a dose for newborn babies. Parents should not infer that an experimental nanodrug replaces established assessment and clinician-directed treatment. The evidence to watch is independent replication, toxicology, clinical trial registration and outcomes against accepted neonatal-care standards.